Ladarixin, an inhibitor of the interleukin-8 receptors CXCR1 and CXCR2, in new-onset type 1 diabetes: A multicentre, randomized, double-blind, placebo-controlled trial.

Diabetes Obes Metab · 2022 · PMC9540558 · PMID 35589610

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

an increasing trendno p-value reported

The mean (±SD) insulin requirement at screening was 0.325 (±0.1923) IU/kg/day for the LDX group and decreased at week 13 (−0.067 [±0.1774] IU/kg/day); however, an increasing trend was seen at week 26 (−0.011 [±0.2625] IU/kg/day) and week 52 (0.025 [±0.2507] IU/kg/day).

also in 63,971 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.